Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness/Implementation Hybrid Study

NCT ID: NCT06880224

Last Updated: 2025-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-01

Study Completion Date

2028-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Two combination interventions (HIV Case Finding Intervention and HIV Treatment Intervention), each with mHealth and Peer Navigation components, will be evaluated in two 48-week parallel hybrid effectiveness/implementation trials among youth aged 15-24 in Nigeria.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Two combination interventions, each with mHealth and Peer Navigation components, will be evaluated in two 48-week parallel hybrid effectiveness/implementation trials among youth aged 15-24 in Nigeria:

1. HIV Case Finding Intervention: single arm trial of an HIV case finding and linkage to care intervention targeting young men at risk of HIV infection (n = 6000), particularly young men who have sex with men (YMSM) in Akwa Ibom, Benue, Enugu, Kano, Taraba, and Lagos states who complete HIV testing.

Objectives: To determine the effectiveness of the intervention to:
* identify youth living with HIV, particularly YMSM and
* link those who test HIV-positive to HIV care
* pre-exposure prophylaxis (PrEP) initiation (uptake) among those who test HIV-negative.
2. HIV Treatment Intervention: randomized controlled trial of a medication adherence and viral suppression intervention among youth newly diagnosed with HIV and initiating antiretroviral therapy (ART) for the first time (n = 600) at the participating clinical sites.

Objectives: To determine the effectiveness of the intervention on

* viral suppression and
* adherence to ART
* success of implementation in the target populations

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adolescent HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a hybrid effectiveness/implementation trial with an HIV Case Finding Intervention "Arm" and a parallel HIV Treatment Intervention "Arm" that is a randomized controlled trial.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV Case Finding Intervention

Combination HIV case finding and linkage to care intervention

Group Type EXPERIMENTAL

Testing Peer navigation

Intervention Type BEHAVIORAL

Peer navigators will promote HIV testing in YMSM and linkage to care if HIV-positive

PrEP Intervention

Intervention Type BEHAVIORAL

Motivational-interviewing to promote uptake of PrEP among those who test HIV-negative

Social Media Outreach

Intervention Type BEHAVIORAL

Social media outreach to identify youth at risk for HIV

HIV Treatment Intervention

Combination HIV treatment intervention vs. standard of care adherence among youth newly diagnosed with HIV and initiating ART

Group Type EXPERIMENTAL

Treatment Peer Navigation

Intervention Type BEHAVIORAL

Peer navigators will provide assistance and support to youth with HIV to optimize adherence to ART

SMS Test messaging

Intervention Type BEHAVIORAL

Text (SMS) messages to remind and encourage youth to adhere to their ART

Adherence standard of care

Intervention Type OTHER

Standard of care HIV treatment adherence

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Testing Peer navigation

Peer navigators will promote HIV testing in YMSM and linkage to care if HIV-positive

Intervention Type BEHAVIORAL

PrEP Intervention

Motivational-interviewing to promote uptake of PrEP among those who test HIV-negative

Intervention Type BEHAVIORAL

Treatment Peer Navigation

Peer navigators will provide assistance and support to youth with HIV to optimize adherence to ART

Intervention Type BEHAVIORAL

Social Media Outreach

Social media outreach to identify youth at risk for HIV

Intervention Type BEHAVIORAL

SMS Test messaging

Text (SMS) messages to remind and encourage youth to adhere to their ART

Intervention Type BEHAVIORAL

Adherence standard of care

Standard of care HIV treatment adherence

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

HIV Case Finding Intervention:

* Aged 15 to 24
* Male birth sex of any current gender identity
* Understand basic English, Yoruba, Hausa, Igbo or Pidgin English For the PrEP component, must also be HIV-negative

HIV Treatment Intervention:

* Aged 15 to 24
* HIV seropositive
* Initiating ART for the first time at a Clinical Research Performance Site (CRPS) clinic or satellite clinic
* Understand basic English, Yoruba, Hausa, Igbo or Pidgin English
* Intention to remain a CRPS patient during follow-up

Exclusion Criteria

* Unable to provide consent
* No parental permission if aged 15 and not emancipated
Minimum Eligible Age

15 Years

Maximum Eligible Age

24 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role collaborator

Northwestern University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Robert Garofalo

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Garofalo, MD

Role: PRINCIPAL_INVESTIGATOR

Northwestern University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Uyo Teaching Hospital

Uyo, Akwa Ibom State, Nigeria

Site Status RECRUITING

Federal Medical Center

Makurdi, Benue State, Nigeria

Site Status RECRUITING

University of Nigeria Teaching Hospital

Enugu, Enugu State, Nigeria

Site Status RECRUITING

Aminu Kano Teaching Hospital

Kano, Kano State, Nigeria

Site Status RECRUITING

Lagos University Teaching Hospital

Lagos, Lagos, Nigeria

Site Status RECRUITING

Taraba State Specialist Hospital

Jalingo, Taraba State, Nigeria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Nigeria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Robert Garofalo, MD

Role: CONTACT

312-227-7740

Lisa M Kuhns, PhD

Role: CONTACT

312-227-7740

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ofonime Dixon-Umo, MBBS

Role: primary

Bem Tar, MBBS

Role: primary

Chinwe Chukwuka, MBBS

Role: primary

Musa Babashani, MBBS

Role: primary

Sulaimon Akanmu, MBBS

Role: primary

Dashe Dasogot, MBBS

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UG1HD113160

Identifier Type: NIH

Identifier Source: secondary_id

View Link

iCARE Plus

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.